Darmerica LLC Initiates Pressing Recall after Dangerous Labeling Error
Darmerica LLC Initiates Pressing Recall after Dangerous Labeling Error
A label mix-up at the production and distribution level of the prescription drug manufacturing process could have a dangerous trickle-down effect on unknowing consumers. On September 12, 2019, the FDA announced that Darmerica LLC is voluntarily recalling two lots of Quinacrine Dichloride, an “active pharmaceutical ingredient” (API) shipped in bulk to pharmacies. A label mix-up has resulted in pharmacies, which typically use the ingredient in combination with others to mass-produce the final medication, receiving Artemisinin API as opposed to Quinacrine API. Quinacrine is an ingredient used as an antiprotozoal, antirheumatic, intrapleural sclerosing agent featured in drugs prescribed to fight parasitic worms, lupus, giardiasis, malignant effusions, and rheumatoid arthritis. What pharmacies that purchased the affected lots actually received is Artemisinin, an ingredient found in drugs used to fight malaria and schizophrenia. According to the FDA announcement, consumers who then purchase prescription drugs containing Artemisinin are at risk of worsening their diagnosed disease, which could necessitate medical or surgical intervention.
If you or a loved one have suffered adverse health effects you have reason to believe were caused by the medication mix-up, contact one of the experienced defective drug attorneys at Burg Simpson today to discuss your legal rights. Call us at 1-800-713-9340 or fill out our contact form for a FREE no-obligation consultation today.
